Welcome to Tianjin Medical University Cancer Institute & Hospital
Tianjin Medical University Cancer Institute & Hospital (TMUCIH) is one of the largest specialized hospitals in China with integrated patient care, education, training, research and preventative medicine. It has 2316 beds, 46 clinical and diagnostic departments and 13 basic research departments. In 2013, TMUCIH was designated as National Clinical Research Center for Cancer by the Ministry of Science and Technology of The People’s Republic of China. In 2017, Oncology was selected as the National “World-Class” Academic Development Program in Tianjin Medical University by the Ministry of Education, the Ministry of Finance, and the National Development and Reform Commission.
The most recognized specialties in the hospital are basic and clinical research on breast cancer, lung cancer, esophageal cancer, liver cancer, head & neck cancer, biotherapy, molecular imaging, radiation oncology, medical oncology, pathology as well as epidemiology. TMUCIH has launched “Advanced National Oncologists and pathologists training course” commissioned by the Ministry of Health since 1954. TMUCIH issued the first cancer journal “Chinese Journal of Clinical Oncology (CJCO)” in 1963, which has become one of the major oncology journals in China. The English version of CJCO 《Cancer Biology & Medicine》 was launched in 2004. According to the Journal Citation Reports (2018), the first impact factor (2017) of Cancer Biology & Medicine is 4.607.
TMUCIH strives for excellence, strict management and world-class service to fulfill our hospital motto of “Providing patients with uttermost integrity and state-of-art medicine and improving our profession with ingenuity and innovation”.
We are confident that we will offer the best treatment and care for cancer patients through promoting cancer research, treatment, and education.